EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #73582_C
表观遗传修饰剂；抑制组蛋白去乙酰化酶（HDAC）6
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
CAY10603是一种选择性强效组蛋白去乙酰化酶6 (HDAC6；IC₅₀=0.002 nM）的抑制剂（Kozikowski et al.）。HDAC6可使组蛋白N端赖氨酸残基去乙酰化。HDAC6还通过高乙酰化作用来调节热休克蛋白90（hsp90）（Rao et al.）。
癌症研究
·抑制多种胰腺癌细胞系（IC₅₀=0.1-1 μM）和卵巢癌细胞系SCCOHT的生长（Kozikowski et al.; Wang et al.）。
细胞类型
癌细胞及细胞系
种属
人，小鼠，非人灵长类，其它细胞系，大鼠
研究领域
癌症
CAS 编号
1045792-66-2
化学式
C₂₂H₃₀N₄O₆
纯度
≥ 95 %
通路
表观遗传学
靶点
HDAC
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
相关材料与文献
文献 (2)
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008 SEP
Abstract
Histone deacetylase 6 (HDAC6) is a heat shock protein 90 (hsp90) deacetylase. Treatment with pan-HDAC inhibitors or depletion of HDAC6 by siRNA induces hyperacetylation and inhibits ATP binding and chaperone function of hsp90. Treatment with 17-allylamino-demothoxy geldanamycin (17-AAG) also inhibits ATP binding and chaperone function of hsp90, resulting in polyubiquitylation and proteasomal degradation of hsp90 client proteins. In this study, we determined the effect of hsp90 hyperacetylation on the anti-hsp90 and antileukemia activity of 17-AAG. Hyperacetylation of hsp90 increased its binding to 17-AAG, as well as enhanced 17-AAG-mediated attenuation of ATP and the cochaperone p23 binding to hsp90. Notably, treatment with 17-AAG alone also reduced HDAC6 binding to hsp90 and induced hyperacetylation of hsp90. This promoted the proteasomal degradation of HDAC6. Cotreatment with 17-AAG and siRNA to HDAC6 induced more inhibition of hsp90 chaperone function and depletion of BCR-ABL and c-Raf than treatment with either agent alone. In addition, cotreatment with 17-AAG and tubacin augmented the loss of survival of K562 cells and viability of primary acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) samples. These findings demonstrate that HDAC6 is an hsp90 client protein and hyperacetylation of hsp90 augments the anti-hsp90 and antileukemia effects of 17-AAG.
Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. Journal of medicinal chemistry 2008 AUG
Abstract
A series of hydroxamate based HDAC inhibitors containing a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddition chemistry. An HDAC6 selective inhibitor having a potency of approximately 2 picomolar was identified. Some of the compounds were examined for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA. This research provides valuable, new molecular probes for use in exploring HDAC biology.
更多信息
| 种属 | Human, Mouse, Non-Human Primate, Other, Rat |
|---|---|
| Cas Number | 1045792-66-2 |
| Chemical Formula | C₂₂H₃₀N₄O₆ |
| 纯度 | ≥ 95% |
| Target | HDAC |
| Pathway | Epigenetic |
相关产品
-
ALDEFLUOR™工具用于鉴定、评估和分离表达高水平ALDH的干细胞和祖细胞
-
IntestiCult™ 类器官生长培养基 (小鼠)用于建立和维持小鼠肠道类器官的培养基
-
曲古抑菌素 A（Trichostatin A）表观遗传修饰剂；抑制组蛋白去乙酰化酶 (HDAC)1 和 HDAC6
